S&P 500   3,887.43 (+2.00%)
DOW   31,574.48 (+2.08%)
QQQ   319.50 (+1.71%)
AAPL   124.79 (+2.91%)
MSFT   235.67 (+1.42%)
FB   259.28 (+0.64%)
GOOGL   2,042.80 (+1.03%)
TSLA   700.32 (+3.67%)
AMZN   3,109.21 (+0.53%)
NVDA   544.44 (-0.75%)
BABA   239.98 (+0.93%)
CGC   34.62 (+5.71%)
GE   13.21 (+5.34%)
MU   93.60 (+2.26%)
NIO   48.89 (+6.79%)
AMD   84.80 (+0.34%)
T   28.32 (+1.54%)
F   11.90 (+1.71%)
ACB   11.18 (+6.27%)
DIS   194.15 (+2.70%)
BA   225.90 (+6.55%)
NFLX   547.59 (+1.62%)
BAC   35.62 (+2.62%)
S&P 500   3,887.43 (+2.00%)
DOW   31,574.48 (+2.08%)
QQQ   319.50 (+1.71%)
AAPL   124.79 (+2.91%)
MSFT   235.67 (+1.42%)
FB   259.28 (+0.64%)
GOOGL   2,042.80 (+1.03%)
TSLA   700.32 (+3.67%)
AMZN   3,109.21 (+0.53%)
NVDA   544.44 (-0.75%)
BABA   239.98 (+0.93%)
CGC   34.62 (+5.71%)
GE   13.21 (+5.34%)
MU   93.60 (+2.26%)
NIO   48.89 (+6.79%)
AMD   84.80 (+0.34%)
T   28.32 (+1.54%)
F   11.90 (+1.71%)
ACB   11.18 (+6.27%)
DIS   194.15 (+2.70%)
BA   225.90 (+6.55%)
NFLX   547.59 (+1.62%)
BAC   35.62 (+2.62%)
S&P 500   3,887.43 (+2.00%)
DOW   31,574.48 (+2.08%)
QQQ   319.50 (+1.71%)
AAPL   124.79 (+2.91%)
MSFT   235.67 (+1.42%)
FB   259.28 (+0.64%)
GOOGL   2,042.80 (+1.03%)
TSLA   700.32 (+3.67%)
AMZN   3,109.21 (+0.53%)
NVDA   544.44 (-0.75%)
BABA   239.98 (+0.93%)
CGC   34.62 (+5.71%)
GE   13.21 (+5.34%)
MU   93.60 (+2.26%)
NIO   48.89 (+6.79%)
AMD   84.80 (+0.34%)
T   28.32 (+1.54%)
F   11.90 (+1.71%)
ACB   11.18 (+6.27%)
DIS   194.15 (+2.70%)
BA   225.90 (+6.55%)
NFLX   547.59 (+1.62%)
BAC   35.62 (+2.62%)
S&P 500   3,887.43 (+2.00%)
DOW   31,574.48 (+2.08%)
QQQ   319.50 (+1.71%)
AAPL   124.79 (+2.91%)
MSFT   235.67 (+1.42%)
FB   259.28 (+0.64%)
GOOGL   2,042.80 (+1.03%)
TSLA   700.32 (+3.67%)
AMZN   3,109.21 (+0.53%)
NVDA   544.44 (-0.75%)
BABA   239.98 (+0.93%)
CGC   34.62 (+5.71%)
GE   13.21 (+5.34%)
MU   93.60 (+2.26%)
NIO   48.89 (+6.79%)
AMD   84.80 (+0.34%)
T   28.32 (+1.54%)
F   11.90 (+1.71%)
ACB   11.18 (+6.27%)
DIS   194.15 (+2.70%)
BA   225.90 (+6.55%)
NFLX   547.59 (+1.62%)
BAC   35.62 (+2.62%)
Log in
OTCMKTS:TRLPF

Acerus Pharmaceuticals Stock Forecast, Price & News

$0.12
0.00 (-3.75 %)
(As of 04/30/2019)
Add
Compare
Today's Range
$0.12
Now: $0.12
$0.12
50-Day Range
$0.03
MA: $0.05
$0.12
52-Week Range
$0.08
Now: $0.12
$0.34
Volume25,000 shs
Average Volume5,474 shs
Market Capitalization$29.87 million
P/E RatioN/A
Dividend YieldN/A
Beta2.52
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Acerus Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:TRLPF
CUSIPN/A
CIKN/A
Phone416-679-0771
Employees29
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.38 million

Profitability

Net Income$-18,790,000.00
Net Margins-254.66%

Miscellaneous

Market Cap$29.87 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.50 out of 5 stars

Medical Sector

1499th out of 1,962 stocks

Pharmaceutical Preparations Industry

650th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.12
0.00 (-3.75 %)
(As of 04/30/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive TRLPF News and Ratings via Email

Sign-up to receive the latest news and ratings for TRLPF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acerus Pharmaceuticals (OTCMKTS:TRLPF) Frequently Asked Questions

What stocks does MarketBeat like better than Acerus Pharmaceuticals?

Wall Street analysts have given Acerus Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acerus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) released its earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.01). The specialty pharmaceutical company earned $1.58 million during the quarter. Acerus Pharmaceuticals had a negative net margin of 254.66% and a negative trailing twelve-month return on equity of 346.72%.
View Acerus Pharmaceuticals' earnings history
.

How has Acerus Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Acerus Pharmaceuticals' stock was trading at $0.0441 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TRLPF shares have increased by 161.9% and is now trading at $0.1155.
View which stocks have been most impacted by COVID-19
.

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the following people:
  • Ms. Patricia Symmes, Chief Operating Officer
  • Dr. Nathan Bryson, Chief Scientific Officer
  • Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
  • Mr. Edward Gudaitis, Pres , CEO & Director
  • Mr. Robert M. Motz, Chief Financial Officer

Who are some of Acerus Pharmaceuticals' key competitors?

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TRLPF."

How do I buy shares of Acerus Pharmaceuticals?

Shares of TRLPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acerus Pharmaceuticals' stock price today?

One share of TRLPF stock can currently be purchased for approximately $0.12.

How much money does Acerus Pharmaceuticals make?

Acerus Pharmaceuticals has a market capitalization of $29.87 million and generates $7.38 million in revenue each year.

How many employees does Acerus Pharmaceuticals have?

Acerus Pharmaceuticals employs 29 workers across the globe.

What is Acerus Pharmaceuticals' official website?

The official website for Acerus Pharmaceuticals is www.aceruspharma.com.

Where are Acerus Pharmaceuticals' headquarters?

Acerus Pharmaceuticals is headquartered at 2486 Dunwin Drive, Mississauga A6, L5L 1J9.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The specialty pharmaceutical company can be reached via phone at 416-679-0771 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.